Skip to main content

Electroporation-Mediated siRNA Delivery into Tumors

  • Protocol
  • First Online:
Electroporation Protocols

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1121))

Abstract

Electroporation-mediated gene transfer (electro-transfection) is a powerful tool to introduce nucleic acid compounds such as plasmid DNAs, antisense oligonucleotides, and short interfering RNAs (siRNAs) into the cells. Electro-transfection is a physical gene transfer method that utilizes an electrostatic field generated with an electroporator apparatus. Here, we demonstrate a practical protocol for electro-transfection (electro-delivery) of siRNA into cells in vivo and further demonstrate the application of the method to cancer therapy. We successfully developed an original electrode (the plate and fork-type electrode) and used it for in vivo electro-delivery of siRNA. Vascular endothelial growth factor (VEGF), an angiogenic factor, was chosen as a model target gene. Electro-delivery of an siRNA targeting VEGF into the xenografted tumors in nude mice significantly suppressed the growth of tumors. By repeating the therapy with a chemically modified siRNA after an interval of 20 days, satisfactory anticancer effects were achieved.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T (2001) Duplexes of 21-nucleotideRNAs mediate interference in cultured mammalian cells. Nature 411:494–498

    Article  CAS  PubMed  Google Scholar 

  2. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391:806–811

    Article  CAS  PubMed  Google Scholar 

  3. Carpenter AE, Sabatini DM (2004) Systematic genome-wide screens of gene function. Nat Rev Genet 5:11–22

    Article  CAS  PubMed  Google Scholar 

  4. Zheng L, Liu J, Batalov S et al (2004) An approach to genomewide screens of expressed small interfering RNAs in mammalian cells. Proc Natl Acad Sci USA 101:135–140

    Article  CAS  PubMed  Google Scholar 

  5. Karagiannis TC, El-Osta A (2004) Mechanism of RNA interference, in vivo and potential clinical applications. Cancer Biol Ther 3:1069–1074

    Article  CAS  PubMed  Google Scholar 

  6. Ryther RCC, Flynt AS, Phillips JA III, Patton JG (2005) siRNA therapeutics: big potential from small RNAs. Gene Ther 12:5–11

    Article  CAS  PubMed  Google Scholar 

  7. Takei Y, Kadomatsu K, Yuzawa Y, Matsuo S, Muramatsu T (2004) A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res 64:3365–3370

    Article  CAS  PubMed  Google Scholar 

  8. Folkman J (1971) Tumor angiogenesis: therapeutic implications. New Engl J Med 285:1182–1186

    Article  CAS  PubMed  Google Scholar 

  9. Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1:27–31

    Article  CAS  PubMed  Google Scholar 

  10. Takei Y, Nemoto T, Mu P, Fujishima T, Ishimoto T, Hayakawa Y, Yuzawa Y, Matsuo S, Muramatsu T, Kadomatsu K (2008) In vivo silencing of a molecular target by short interfering RNA electroporation: tumor vascularization correlates to delivery efficiency. Mol Cancer Ther 7:211–221

    Article  CAS  PubMed  Google Scholar 

  11. Takei Y, Kadomatsu K, Goto T, Muramatsu T (2006) Combinational antitumor effect of siRNA against midkine and paclitaxel on growth of human prostate cancer xenografts. Cancer 107:864–873

    Article  CAS  PubMed  Google Scholar 

  12. Takei Y, Kadomatsu K, Matsuo S et al (2001) Antisense oligodeoxynucleotide targeted to Midkine, a heparin-binding growth factor, suppresses tumorigenicity of mouse rectal carcinoma cells. Cancer Res 61:8486–8491

    CAS  PubMed  Google Scholar 

  13. Takei Y, Kadomatsu K, Itoh H et al (2002) 5′-,3′-inverted thymidine-modified antisense oligodeoxynucleotide targeting midkine. Its design and application for cancer therapy. J Biol Chem 277:23800–23806

    Article  CAS  PubMed  Google Scholar 

  14. Takei Y, Kadomatsu K, Yuasa K, Sato W, Muramatsu T (2005) Morpholino antisense oligomer targeting human midkine: its application for cancer therapy. Int J Cancer 114:490–497

    Article  CAS  PubMed  Google Scholar 

  15. Mu P, Nagahara S, Makita N, Tarumi Y, Kadomatsu K, Takei Y (2009) Systemic delivery of siRNA specific to tumor mediated by atelocollagen: combined therapy using siRNA targeting Bcl-xL and cisplatin against prostate cancer. Int J Cancer 125:2978–2990

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this protocol

Cite this protocol

Takei, Y. (2014). Electroporation-Mediated siRNA Delivery into Tumors. In: Li, S., Cutrera, J., Heller, R., Teissie, J. (eds) Electroporation Protocols. Methods in Molecular Biology, vol 1121. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4614-9632-8_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-9632-8_11

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4614-9631-1

  • Online ISBN: 978-1-4614-9632-8

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics